Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates

In Silico and In Vitro Analysis of Interaction between Ximelagatran and Human Leukocyte Antigen (HLA)-DRB1*07:01

(2017) Makoto Hirasawa et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Highly Potent, Anthracycline-based Antibody–Drug Conjugates Generated by Enzymatic, Site-specific Conjugation

(2017) Nikolas Stefan et al.   MOLECULAR CANCER THERAPEUTICS

Strategies and challenges for the next generation of antibody–drug conjugates

(2017) Alain Beck et al.   NATURE REVIEWS DRUG DISCOVERY

Redox-based reagents for chemoselective methionine bioconjugation

(2017) Shixian Lin et al.   SCIENCE

Pyridazinediones deliver potent, stable, targeted and efficacious antibody–drug conjugates (ADCs) with a controlled loading of 4 drugs per antibody

(2017) Eifion Robinson et al.   RSC Advances

One-Step Conjugation Method for Site-Specific Antibody–Drug Conjugates through Reactive Cysteine-Engineered Antibodies

(2016) Daisuke Shinmi et al.   BIOCONJUGATE CHEMISTRY

Allotype specific interactions of drugs and HLA molecules in hypersensitivity reactions

(2016) Patricia T Illing et al.   CURRENT OPINION IN IMMUNOLOGY

Chemically Programmed Bispecific Antibodies in Diabody Format

(2016) Even Walseng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pharmacokinetics and Tolerability of a Dual Variable Domain Immunoglobulin ABT-981 Against IL-1α and IL-1β in Healthy Subjects and Patients With Osteoarthritis of the Knee

(2016) Matthew P. Kosloski et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates

(2016) Kalli C. Catcott et al.   mAbs

Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody–Drug Conjugates

(2015) Remon van Geel et al.   BIOCONJUGATE CHEMISTRY

Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody–Drug Conjugates Using Click Cycloaddition Chemistry

(2015) Michael P. VanBrunt et al.   BIOCONJUGATE CHEMISTRY

Hydrolytically Stable Site-Specific Conjugation at the N-Terminus of an Engineered Antibody

(2015) Pamela Thompson et al.   BIOCONJUGATE CHEMISTRY

Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development

(2015) Paresh Agarwal et al.   BIOCONJUGATE CHEMISTRY

A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs

(2015) S.-F. Yu et al.   CLINICAL CANCER RESEARCH

Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

(2015) Maria Corinna A Palanca-Wessels et al.   LANCET ONCOLOGY

Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models

(2015) F. Lhospice et al.   MOLECULAR PHARMACEUTICS

Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs

(2015) Christopher R. Behrens et al.   MOLECULAR PHARMACEUTICS

In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab–MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios

(2015) Penny Bryant et al.   MOLECULAR PHARMACEUTICS

An Anti-B7-H4 Antibody–Drug Conjugate for the Treatment of Breast Cancer

(2015) Steven R. Leong et al.   MOLECULAR PHARMACEUTICS

Amgen's bispecific antibody puffs across finish line

(2015) Cormac Sheridan   NATURE BIOTECHNOLOGY

Current ADC Linker Chemistry

(2015) Nareshkumar Jain et al.   PHARMACEUTICAL RESEARCH

An FDA oncology analysis of antibody-drug conjugates

(2015) Haleh Saber et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Insights on the immunogenicity of antibody–drug conjugates

(2015) Montserrat Carrasco-Triguero   Bioanalysis

Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy

(2015) Magdalena Dorywalska et al.   PLoS One

Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency

(2015) Roger R. Beerli et al.   PLoS One

Preparation of Well-Defined Antibody-Drug Conjugates through Glycan Remodeling and Strain-Promoted Azide-Alkyne Cycloadditions

(2014) Xiuru Li et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Production of Site-Specific Antibody–Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System

(2014) Erik S. Zimmerman et al.   BIOCONJUGATE CHEMISTRY

Site-Specific Antibody–Drug Conjugation through Glycoengineering

(2014) Qun Zhou et al.   BIOCONJUGATE CHEMISTRY

Aldehyde Tag Coupled with HIPS Chemistry Enables the Production of ADCs Conjugated Site-Specifically to Different Antibody Regions with Distinct in Vivo Efficacy and PK Outcomes

(2014) Penelope M. Drake et al.   BIOCONJUGATE CHEMISTRY

Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer

(2014) John M. Lambert et al.   JOURNAL OF MEDICINAL CHEMISTRY

Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar

(2014) Zhongyu Zhu et al.   mAbs

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

(2014) Robert P Lyon et al.   NATURE BIOTECHNOLOGY

A general approach to site-specific antibody drug conjugates

(2014) Feng Tian et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Chemically programmed antibodies

(2014) Christoph Rader   TRENDS IN BIOTECHNOLOGY

Metabolic Engineering of Monoclonal Antibody Carbohydrates for Antibody–Drug Conjugation

(2013) Nicole M. Okeley et al.   BIOCONJUGATE CHEMISTRY

A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology

(2013) Scott C. Jeffrey et al.   BIOCONJUGATE CHEMISTRY

Conjugation Site Heterogeneity Causes Variable Electrostatic Properties in Fc Conjugates

(2013) Nicholas J. Boylan et al.   BIOCONJUGATE CHEMISTRY

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

(2013) M. S. Kung Sutherland et al.   BLOOD

Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates

(2013) Pavel Strop et al.   CHEMISTRY & BIOLOGY

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

(2013) Vibha Jawa et al.   CLINICAL IMMUNOLOGY

BCR–ABL1expression in multiple myeloma cells: A case of mistaken identity?

(2013) Roderick A. F. MacLeod et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reply to MacLeod et al.: Multiple myeloma plasma cells have chameleon characteristics

(2013) Susanne B. Breitkopf et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

(2012) Ben-Quan Shen et al.   NATURE BIOTECHNOLOGY

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

(2012) J. Y. Axup et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Physicochemical Stability of the Antibody−Drug Conjugate Trastuzumab-DM1: Changes due to Modification and Conjugation Processes

(2010) Aditya A. Wakankar et al.   BIOCONJUGATE CHEMISTRY

Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics

(2010) C. Andrew Boswell et al.   BIOCONJUGATE CHEMISTRY

Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

(2010) J. R. Junutula et al.   CLINICAL CANCER RESEARCH

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

(2010) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

β-Lactam-based approach for the chemical programming of aldolase antibody 38C2

(2009) Julia I. Gavrilyuk et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

(2009) D. Dornan et al.   BLOOD

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo

(2009) H. Ikeda et al.   CLINICAL CANCER RESEARCH

Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics

(2009) Anne S. De Groot et al.   CLINICAL IMMUNOLOGY

Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates

(2008) Stephen C. Alley et al.   BIOCONJUGATE CHEMISTRY

Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"

(2008) A. S. De Groot et al.   BLOOD

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY